This study evaluates the applicability and clinical efficacy of conventional music therapy and digital music rehabilitation for dementia in home and care home settings.
Rationale: In persons with dementia (PWDs), music-based interventions have shown positive effects on emotional, behavioural and cognitive symptoms as well as on psychological well-being and quality of life. Despite the evidence for the efficacy of music in PWDs, many issues surround the practicalities of music interventions, especially regarding their applicability, scalability, and optimization across the dementia care continuum. Moreover, the individual factors affecting the treatment outcomes of music-based interventions remain largely unexplored in dementia. Aims: The purpose of this randomized controlled trial (RCT) is to determine the applicability and clinical efficacy of conventional music therapy and digital music rehabilitation for dementia in both home and care home settings. Specifically, the RCT seeks to determine (i) can conventional music therapy (CMT) and digital music rehabilitation (DMR) enhance or support cognitive function, mood, and quality of life in dementia compared to standard care; (ii) how does the efficacy of CMT and DMR differ in the different stages of dementia; and (iii) how do baseline demographic factors (e.g., age, gender, education), musical factors (musical background, music cognition) and neural factors (e.g., extent of neuropathology, preservation of music networks) affect the efficacy of the music interventions. Methods: Participants are 192 PWDs across the dementia care continuum (PWDs with mild-moderate dementia living at home and PWDs with moderate-severe dementia living in care homes; N=96 each). Following a three-arm parallel-group RCT design, the PWDs living at home and at care homes are randomized into three groups (CMT, DMR, standard care; N=32 each\]. The CMT and DMR comprise passive and active engagement with music over 10 weeks (2x60 min sessions/week), implemented either by a music therapist (CMT) or using a novel digital music content service (DMR). To investigate the efficacy of the music interventions, participants complete measures of cognitive functioning (neuropsychological tests) and mood and quality of life (questionnaires, clinical scales), which are assessed at three time points: baseline (pre-intervention), 3-month stage (post-intervention) and 6-month stage (follow-up). Additionally, family member and caregivers of PWDs are asked to answer questionnaires on the psychological well-being of the PWD (informant-report) and themselves (self-report). To explore the individual musical and neural factors that may affect the efficacy of music interventions, participants also complete a musical assessment battery as well as electroencephalography (EEG) and structural and functional MRI (s/fMRI) measurements at baseline.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
192
CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
University of Helsinki / Faculty of Medicine / Department of Psychology
Helsinki, Finland
RECRUITINGChange from baseline in the MoCA score at 3-month stage
Montreal Cognitive Assessment (MoCA) score (range 0-30, higher score indicates better outcome), measures general cognitive function
Time frame: Baseline and 3-month stage
Change from baseline in the CERAD total score at 3-month stage
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) total score (Chandler score, range 0-100, higher score indicates better outcome), measures general cognitive function
Time frame: Baseline and 3-month stage
Change from baseline in the MoCA score at 6-month stage
Montreal Cognitive Assessment (MoCA) score (range 0-30, higher score indicates better outcome), measures general cognitive function
Time frame: Baseline and 6-month stage
Change from baseline in the CERAD total score at 6-month stage
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) total score (Chandler score, range 0-100, higher score indicates better outcome), measures general cognitive function
Time frame: Baseline and 6-month stage
Change from baseline in the MoCA Fluency score at 3-month and 6-month stages
Montreal Cognitive Assessment (MoCA) Fluency subtest score (phonemic fluency; min: 0, max: no upper limit, higher score indicates better outcome), measures language skills
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Fluency score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Fluency subtest score (semantic fluency; min: 0, max: no upper limit, higher score indicates better outcome), measures language skills
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Naming score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Naming subtest score (range: 0-15, higher score indicates better outcome), measures language skills
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Constructional Praxis score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Constructional Praxis subtest score (range: 0-11, higher score indicates better outcome), measures visuoconstructive function
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Word List Learning score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Learning subtest score (range: 0-30, higher score indicates better outcome), measures verbal learning
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Word List Recall score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Recall subtest score (range: 0-10, higher score indicates better outcome), measures delayed spontaneous verbal recall
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the CERAD Word List Recognition score at 3-month and 6-month stages
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Recognition subtest score (range: 0-20, higher score indicates better outcome), measures delayed cued verbal recall
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the WMS-IV Logical Memory I score at 3-month and 6-month stages
Wechsler Memory Scale IV (WMS-IV) Logical Memory I subtest score (range: 0-56, higher score indicates better outcome), measures immediate verbal recall
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the WMS-IV Logical Memory II score at 3-month and 6-month stages
Wechsler Memory Scale IV (WMS-IV) Logical Memory II subtest score (range: 0-28, higher score indicates better outcome), measures delayed verbal recall
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the IFS total score at 3-month and 6-month stages
INECO Frontal Screening (IFS) total score (range 0-30, higher score indicates better outcome), measures executive function and working memory
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the IFS Executive subscore at 3-month and 6-month stages
INECO Frontal Screening (IFS) Executive subscore (summary score of the Motor Series, Conflicting Instructions, Go-No Go, Proverbs and Hayling Test subtests, range 0-18, higher score indicates better outcome), measures executive function
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the IFS Working memory subscore at 3-month and 6-month stages
INECO Frontal Screening (IFS) Working memory subscore (summary score of the Digits Backward, Verbal Working Memory and Spatial Working Memory subtests, range 0-12, higher score indicates better outcome), measures working memory
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in autobiographical memory score at 3-month and 6-month stages
Custom-made autobiographical memory questionnaire, percentage score (range 0-100, higher score indicates better outcome; also qualitative data collected), measures subjective and objective autobiographical memory
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the MADRS score at 3-month and 6-month stages
Montgomery-Åsberg Depression Rating Scale (MADRS) score (range 0-60, higher score indicates worse outcome), measures depression symptoms
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the PROMIS Depression score at 3-month and 6-month stages
Patient-Reported Outcomes Measurement Information System (PROMIS) Depression scale score (range 8-40, higher score indicates worse outcome), measures depression symptoms
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the PROMIS Anxiety score at 3-month and 6-month stages
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety scale score (range 8-40, higher score indicates worse outcome), measures anxiety symptoms
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the NPI-Q Severity score at 3-month and 6-month stages
Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity scale score (range 0-36, higher score indicates worse outcome), measures the severity of neuropsychiatric symptoms
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the NPI-Q Distress score at 3-month and 6-month stages
Neuropsychiatric Inventory Questionnaire (NPI-Q) Distress scale score (range 0-60, higher score indicates worse outcome), measures the distress caused by the neuropsychiatric symptoms on caregivers
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the NPI-Q total score at 3-month and 6-month stages
Neuropsychiatric Inventory Questionnaire (NPI-Q) total score (range 0-180, calculated as Severity x Distress, higher score indicates worse outcome), measures the total level of neuropsychiatric symptoms
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the QoL-AD score at 3-month and 6-month stages
Quality of Life in Alzheimer's Disease (QoL-AD) score (range 15-60, higher score indicates better outcome), measures quality of life
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the EuroQol EQ-5D-5L Health index score at 3-month and 6-month stages
EuroQol EQ-5D-5L Health index score (range 0-1, higher score indicates better outcome), measures health-related quality of life
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the EuroQol EQ-5D-5L Health VAS score at 3-month and 6-month stages
EuroQol EQ-5D-5L Health VAS score (range 0-100, higher score indicates better outcome), measures general health
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the caregiver GHQ-12 score at 3-month and 6-month stages
General Health Questionnaire 12 (GHQ-12) score (caregiver self-report; range 0-36, higher score indicates worse outcome), measures stress and psychological well-being
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the caregiver ZBI-12 score at 3-month and 6-month stages
Zarit Burden Interview 12 (ZBI-12) score (caregiver self-report; range 0-48, higher score indicates worse outcome), measures caregiver burden
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the UWES-9 score at 3-month and 6-month stages
Utrecht Work Engagement Scale 9 (UWES-9) score (nurse self-report; range 0-54, higher score indicates better outcome), measures occupational well-being
Time frame: Baseline, 3-month stage and 6-month stage
Change from baseline in the PCTB score at 3-month and 6-month stages
Professional Care Team Burden (PCTB) score (nurse self-report; range 0-40, higher score indicates worse outcome), measures professional care team burden
Time frame: Baseline, 3-month stage and 6-month stage